Answers are grounded in this paper and cite their sources.
Immune-based interventions to treat or prevent autoimmune disorders are opening up entirely novel therapeutic avenues. Presently, systemic immune modulators such as antibodies to cytokines or cell-surface molecules (i.e., costimulators) are undergoing clinical testing or are already in use. The next generation of interventions will function in an antigen-specific way. These strategies are more difficult to design, because successful immunization or vaccination has to be monitored on an individual basis and dose/route/timing considerations play an essential role. Both will be discussed in this chapter and suitable combinatorial approaches will be suggested.
No takes yet. Share an insight, caveat, or question.
Matthias G. von Herrath (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: